gabapentin has been researched along with Impairment, Light Touch Sensation in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 9.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 5.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Many patients with neuropathic pain have coexistent sensory deficits." | 1.31 | Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin. ( Chong, MS; Hanna, M; Smith, TE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van de Vusse, AC | 1 |
| Stomp-van den Berg, SG | 1 |
| Kessels, AH | 1 |
| Weber, WE | 1 |
| Povedano, M | 1 |
| Gascón, J | 1 |
| Gálvez, R | 1 |
| Ruiz, M | 1 |
| Rejas, J | 1 |
| Chong, MS | 1 |
| Smith, TE | 1 |
| Hanna, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271] | 5 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Due to limited population of research participants.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3
| Intervention | units on the VAS (Mean) |
|---|---|
| CRPS I Pain Subjects | 3.67 |
1 trial available for gabapentin and Impairment, Light Touch Sensation
| Article | Year |
|---|---|
Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].
Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2004 |
2 other studies available for gabapentin and Impairment, Light Touch Sensation
| Article | Year |
|---|---|
Cognitive function impairment in patients with neuropathic pain under standard conditions of care.
Topics: Adult; Aged; Amines; Analgesics; Cognition Disorders; Cohort Studies; Cyclohexanecarboxylic Acids; F | 2007 |
Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin.
Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |